The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the early asthmatic response to inhaled allergen Source: Annual Congress 2011 - Asthma management and response Year: 2011
The in vivo activity of AWD 12-353, a potent phosphodiesterase 4 (PDE) inhibitor for the treatment of allergic asthma and COPD Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003
The contents of α1-acid glycoprotein (α1-AGP) and metabolites of nitric oxide (NO) in nasal lavage fluid (NLF) of patients with bronchial asthma (BA) and allergic rhinitis (AR) and house dust mites (HDM) exposure Source: Eur Respir J 2001; 18: Suppl. 33, 43s Year: 2001
The role of the enzymatic activity of the house dust mite antigen Der p 1 in enhancing its allergenicity Source: ISSN=1025-448x, ISBN=1-904097-24-3, page=153 Year: 2002
Cytokines and alpha-1proteinase inhibitor (A1 PI) levels in meat wrappers‘ asthma Source: Annual Congress 2010 - Occupational asthma Year: 2010
Role of allergen exposure on the development of asthma in childhood Source: Eur Respir Mon 2012; 56: 128-133 Year: 2012
The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the allergen induced asthmatic response Source: Annual Congress 2011 - New treatments for airway disease Year: 2011
Bronchial challenge with flour: early response is dependent on the dose of activated allergen inhaled Source: Eur Respir J 2002; 20: 409-416 Year: 2002
Total IgE and Der p 1 (D1) specific IgE in induced sputum (IS) in patients with allergic and non-allergic asthma Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018
Protective effect of a protein epitope mimetic (PEM) CCR10 antagonist, POL7085, in an allergic model of asthma Source: Annual Congress 2011 - Translational models of airway disease Year: 2011
Deficiency of CARS2, a principal cysteine persulfide synthase, aggravated house dust mite-induced allergic inflammation in a mouse model of asthma. Source: Virtual Congress 2020 – New insight into the immunology of asthma and COPD Year: 2020
Effect of a pan-JAK inhibitor pyridone 6 on airway responses in murine asthma model Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010
Anti-inflammatory effects of the JAK inhibitor tofacitinib in two murine house dust mite -driven models of asthma. Source: International Congress 2018 – Novel drug targets for asthma and COPD Year: 2018
Assessment of in vivo 5-lipoxygenase (5-LO) activity in nonatopic and atopic subjects with or without asthma: effects of treatment with the 5-LO inhibitor zileuton Source: Eur Respir J 2003; 22: Suppl. 45, 101s Year: 2003
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
The inhaled PDE4 inhibitor GSK256066 significantly inhibits airway responses following allergen challenge in asthmatics Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Quantitative assessment of cysteinyl leukotrienes in human sputum during the allergen-induced asthmatic response and the effect of GSK2190915, a 5-lipoxygenase activating protein (FLAP) inhibitor Source: Annual Congress 2011 - Diagnosis and treatment of inflammatory respiratory diseases Year: 2011
The inhaled PDE4 inhibitor UK-500,001 does not significantly inhibit airway responses to allergen and histamine Source: Annual Congress 2007 - New drugs for asthma Year: 2007
Association between house dust mites (HDM) number in homes and of α1–acid glycoprotein (α1-AGP) level in expired air condensate (EAC) and nasal lavage fluid (NLF) of children with bronchial asthma (BA) and allergic rhinitis (AR) Source: Eur Respir J 2005; 26: Suppl. 49, 693s Year: 2005